Laboratory products
Atlas Biolabs announces its accreditation as a certified Affymetrix DMET™ Service Provider, offering the latest DMET™ Plus Solution from Affymetrix. DMET Plus uses microarray testing to investigate common variations in genes encoding for drug-metabolism enzymes and drug transporters, and to identify their impact on the individual metabolic capacity. Atlas Biolabs is the first European Certified Service Provider to offer the DMET technology for use in molecular pharmacogenetics in Germany.
Allelic variants with catalytic activities different from wild-type forms have been identified for an increasing number of drug-metabolising enzymes and drug transporters. Analysing the diversity of these proteins has become extremely important in the evaluation of drug toxicity. Thus, genotyping patients with respect to a particular genetic variant helps to avoid adverse drug responses, increase treatment efficacy, and achieve both improved healthcare outcomes and substantial economic benefits.
DMET Plus covers a broad range of 1,936 genetic variants across 231 relevant genes in one assay. Moreover, the test inspires high confidence in results and supports the rapid and comprehensive interpretation of genotyping data. DMET Plus will be useful in the discovery of novel biomarkers resulting from pharmacogenetic associations, as well as in the optimisation of drug candidates. DMET could also improve translational and clinical trials by showing the effects of known metabolic pathways in poor drug responders, and confirm metabolic pathway involvement in newly discovered drug-metabolism associations.
“DMET helps translate pharmacogenetics into practice and will take us one step closer to the vision of personalised medicine,” said Patrick Kelly, Director of Sales and Market Development at Atlas Biolabs. “We are excited to offer our customers this new tool, which opens up the possibility of measuring existing and new metabolic pathways in a cost-effective and very reliable way.”
.jpg)
-(2).jpg)
